MXPA02005562A - Superdesintegrante farmaceutico. - Google Patents

Superdesintegrante farmaceutico.

Info

Publication number
MXPA02005562A
MXPA02005562A MXPA02005562A MXPA02005562A MXPA02005562A MX PA02005562 A MXPA02005562 A MX PA02005562A MX PA02005562 A MXPA02005562 A MX PA02005562A MX PA02005562 A MXPA02005562 A MX PA02005562A MX PA02005562 A MXPA02005562 A MX PA02005562A
Authority
MX
Mexico
Prior art keywords
superdisintegrant
superdisintegrants
dosage form
solid dosage
compactibility
Prior art date
Application number
MXPA02005562A
Other languages
English (en)
Inventor
Staniforth John
Original Assignee
Penwest Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penwest Pharmaceuticals Co filed Critical Penwest Pharmaceuticals Co
Publication of MXPA02005562A publication Critical patent/MXPA02005562A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen superdesintegrantes los cuales proporcionan compresabilidad mejorada en comparacion con los superdesintegrantes de la tecnica anterior que no tienen un impacto negativo sobre la compresabilidad de formulaciones que incluyen farmacos en altas dosis, y metodos para obtener los mismos. Los superdesintegrantes incluyen un aglomerado particulado de almidon o celulosa coprocesada y una cantidad suficiente de un agente aditivo para incrementar la compactabilidad del superdesintegrante. El superdesintegrante aumentado proporciona una desintegracion rapida de una forma de desintegracion solida cuando se incorpora en una cantidad suficiente homologa, sin afectar de manera adversa la compactabilidad de la forma de dosificacion solida (en relacion a una forma de dosificacion solida sin el superdesintegrante).
MXPA02005562A 1999-12-06 2000-12-06 Superdesintegrante farmaceutico. MXPA02005562A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16917499P 1999-12-06 1999-12-06
PCT/US2000/032989 WO2001039746A1 (en) 1999-12-06 2000-12-06 Pharmaceutical superdisintegrant

Publications (1)

Publication Number Publication Date
MXPA02005562A true MXPA02005562A (es) 2004-09-10

Family

ID=22614504

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005562A MXPA02005562A (es) 1999-12-06 2000-12-06 Superdesintegrante farmaceutico.

Country Status (11)

Country Link
US (2) US6660303B2 (es)
EP (1) EP1244428A1 (es)
KR (1) KR20020062323A (es)
AU (2) AU771440B2 (es)
BR (1) BR0016482A (es)
CA (1) CA2393231A1 (es)
HU (1) HUP0301333A3 (es)
IL (1) IL150053A0 (es)
MX (1) MXPA02005562A (es)
NO (1) NO20022645L (es)
WO (1) WO2001039746A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204771D0 (en) * 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
AU2003256284A1 (en) * 2002-06-20 2004-01-06 Orapharma, Inc. Rapidly disintegrating formulations for treating or preventing mucositis
SI21221A (sl) * 2002-06-21 2003-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Hitro razpadljive tablete
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20050244490A1 (en) * 2003-12-09 2005-11-03 Michael Otto Dosing methods for beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
EP1725217B1 (en) * 2004-03-10 2008-08-06 Ranbaxy Laboratories, Ltd. Processes for the preparation of solid dosage forms of amorphous valganciclovir hydrochloride
US20050220865A1 (en) * 2004-04-02 2005-10-06 Koleng John J Compressed composition comprising magnesium salt
US8236349B2 (en) * 2004-04-12 2012-08-07 Bend Research Inc. Taste-masked drugs in rupturing multiparticulates
CA2784881C (en) * 2005-02-25 2016-02-09 Takeda Pharmaceutical Company Limited Method for producing granules
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20070043096A1 (en) * 2005-07-18 2007-02-22 Horizon Therapeutics, Inc. Unit dose form with ibuprofen-famotidine admixture
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US10357462B2 (en) * 2006-11-30 2019-07-23 Ben Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
US20100055179A1 (en) * 2006-12-21 2010-03-04 Mallinckrodt Inc. Composition of and Method for Preparing Orally Disintegrating Tablets Containing a High Dose of Pharmaceutically Active Ingredients
JP5637624B2 (ja) * 2009-02-12 2014-12-10 富士化学工業株式会社 崩壊性粒子組成物及びそれを用いた速崩壊性圧縮成型物
EP3138603A1 (en) * 2009-03-20 2017-03-08 Incube Labs, Llc Solid drug delivery apparatus, formulations and methods of use
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
US20160008310A1 (en) 2014-07-11 2016-01-14 Azanta A/S Misoprostol dispersible tablet
EA039069B1 (ru) * 2014-07-11 2021-11-30 Асанта Данмарк А/С Способ обеспечения созревания шейки матки или стимулирования родов, включающий введение фармацевтической композиции мизопростола, и применение мизопростола для изготовления такой композиции
EP4110263A4 (en) * 2020-02-27 2024-04-17 Henkel AG & Co. KGaA PERSONAL CARE PRODUCT AND METHOD FOR PRODUCING A PERSONAL CARE PRODUCT BY A GENERATIVE PROCESS
CN112618503B (zh) * 2021-01-20 2022-04-15 天津市中央药业有限公司 头孢地尼分散片

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3141875A (en) 1961-03-15 1964-07-21 Fmc Corp Crystallite aggregates disintegrated in acid medium
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4772473A (en) 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
US4910023A (en) * 1988-06-09 1990-03-20 Warner-Lambert Company Drug in combination with flavor masking agent and method for making same
HU203041B (en) 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5468286A (en) * 1989-10-25 1995-11-21 National Starch And Chemical Investment Holding Corporation Enzymatically debranched starches as tablet excipients
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
CA2041774C (en) 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5215757A (en) * 1991-03-22 1993-06-01 The Procter & Gamble Company Encapsulated materials
US5272191A (en) 1991-08-21 1993-12-21 Fmc Corporation Cold water soluble films and film forming compositions
CA2140032C (en) 1992-07-24 1999-01-26 Mircea A. Mateescu Cross-linked amylose material for enzymatically controlled drug release
US5616343A (en) 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
US5948438A (en) 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
IL139728A (en) 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US6106865A (en) 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5733578A (en) 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
TW430561B (en) * 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
US5989589A (en) 1997-10-24 1999-11-23 Cartilier; Louis Cross-linked cellulose as a tablet excipient

Also Published As

Publication number Publication date
US6660303B2 (en) 2003-12-09
KR20020062323A (ko) 2002-07-25
CA2393231A1 (en) 2001-06-07
US20020068084A1 (en) 2002-06-06
BR0016482A (pt) 2002-12-24
AU2004202515A1 (en) 2004-07-01
IL150053A0 (en) 2002-12-01
AU771440B2 (en) 2004-03-25
HUP0301333A2 (hu) 2004-05-28
AU2061401A (en) 2001-06-12
NO20022645L (no) 2002-08-01
WO2001039746A1 (en) 2001-06-07
NO20022645D0 (no) 2002-06-05
HUP0301333A3 (en) 2005-06-28
US20050100600A1 (en) 2005-05-12
EP1244428A1 (en) 2002-10-02

Similar Documents

Publication Publication Date Title
MXPA02005562A (es) Superdesintegrante farmaceutico.
IL133397A (en) Pharmaceutical compositions for oral administration comprising an active substance and a cyclodextrin
GEP20053420B (en) Sustained Release Ranolanolazine Formulation
BG104877A (en) N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
HK1067544A1 (en) Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
EP1423107A4 (en) FATTY ALCOHOL DRUG CONJUGATES
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
GEP20053473B (en) High Potency Dihydroergotamine Compositions
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
AU9163701A (en) Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid
RS49723B (sr) Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze
DE60019334D1 (de) Antivirale arznei
PL346764A1 (en) New oral formulation for 5-ht4
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
MXPA03002807A (es) Estabilizacion de formulaciones solidas de farmacos.
MY140127A (en) Pharmaceutical formulation
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
MXPA03001226A (es) Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados.
AP2001002084A0 (en) Orally administered controlled delivery system for once daily adminstration of ciprofloxacin
HK1045937A1 (en) Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof
ATE327738T1 (de) Synergistische füllzusammensetzung
GR3019776T3 (en) Antineoplastic medicament containing octadecyl-[2-(N-methylpiperidino)-ethyl] phosphate and synthesis thereof